Journal of Psychopharmacology
January 6, 2026
Connor J. Maltby, Adam K. Klein, Enya Paschen et al.
3 citations
Background: Psilocybin has shown rapid and sustained antidepressant effects in patients with major depressive disorder, yet the neurobiological mechanisms underlying these outcomes remain unclear. Aims: This study aimed to bridge clinical and preclinical findings by investigating the relationships between 5-HT 2A receptor occupancy (RO) achieved after administration of psilocybin and its...
Journal of Eating Disorders
January 3, 2026
Jesse Dallery, Jennifer L Miller, Jeff Boissoneault et al.
1 citation
Binge Eating Disorder (BED) is the most prevalent eating disorder and is associated with psychiatric comorbidities, health impairments, and decreased quality of life. Emerging evidence suggests that psilocybin-assisted therapy may promote cognitive and emotional flexibility and disrupt maladaptive behavioral patterns, making it a promising candidate for BED treatment. This open-label pilot...
Journal of Psychoactive Drugs
January 2, 2026
Frederick D. Sancilio, Maghsoud Dariani, Purvi Chavda et al.
Anxiety disorders are chronic health conditions affecting the quality of life of millions of people. Psilocin, the active moiety of psilocybin, provides an anxiolytic effect; however, when orally administered as psilocybin, it only offers a moderate level of bioavailability and less predictable pharmacokinetics, potentially making effects after absorption variable and increasing the risk of...
bioRxiv (Cold Spring Harbor Laboratory)
January 2, 2026
Jason C. Slot, Alexander J. Bradshaw, Bryn T. M. Dentinger et al.
preprint
Abstract Production of the psychoactive compound psilocybin is a defining feature of the genus Psilocybe , commonly referred to as “psychedelic mushrooms”. However, Psilocybe fuscofulva is a striking exception within Psilocybe sensu stricto as it lacks the stereotypical blue bruising characteristic of the genus, and psilocybin has not been detected in the species.To investigate the evolutionary...
BMC Psychology
January 2, 2026
Reza Moshfeghinia, Sara Mostafavi, Kimia Jazi et al.
2 citations
Psilocybin may reduce depressive symptoms in cancer patients, with mixed effects on anxiety and time-dependent improvements in spiritual well-being and (in single-arm data) quality of life. Given the small number of studies, high heterogeneity, challenges with blinding/expectancy, and frequent co-intervention with psychotherapy, these findings are preliminary. Larger, rigorously blinded trials...
2026
Zarmeen Zahid, Brandon Weiss, Sandeep Manel Nayak
preprint
This nightmare-focused study was conducted based on data collected in an open-label, controlled treatment pilot trial conducted at the Johns Hopkins Center for Psychedelic and Consciousness Research (CPCR) under an approved protocol (IRB00407008; NCT06407635). Participants completed screening, baseline assessment, four preparatory sessions, two psilocybin dosing sessions, seven post-session...
2026
Yosr Ziadi, Taehwan Park
preprint
Conference poster presented at ISPOR 2026, Philadelphia, May 2026. Co-authors: Yosr Ziadi, Taehwan Park. St. John's University.
Cahiers francophones de soins palliatifs
2026
Michel Dorval, Sue-Ling Chang, Houman Farzin et al.
La psychothérapie assistée par psilocybine représente un ajout prometteur aux interventions de soins palliatifs, pouvant améliorer la qualité de vie en soulageant la détresse existentielle. Malgré sa sécurité et son efficacité, cette thérapie demeure limitée au Canada, soulignant la nécessité d’en améliorer l'accès pour atténuer la souffrance liée à des maladies potentiellement mortelles....
2026
Tom Bielen
preprint
Psilocybin-assisted therapy has produced promising results in clinical trials for depression, but most existing reviews treat major depressive disorder (MDD) and treatment-resistant depression (TRD) as a single category. This conflation is a problem. MDD and TRD differ in diagnostic criteria, illness severity, prior treatment failure, and likely neurobiological profile. Pooling their results...
2026
Irina Dell'Orto
preprint
Background: Psilocybin-assisted therapy (PAT) has demonstrated rapid and substantial antidepressant effects in phase 2 RCTs (Davis et al., 2021; Carhart-Harris et al., 2021), and phase 3 trials are now active (Usona uAspire, NCT06308653). However, three critical gaps remain unresolved in 2025: (1) the durability of effects beyond 12 months has not been established in a controlled design; (2)...